A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)
Clinical trial NCT05616754 · UNKNOWN
Trial details
- NCT number
- NCT05616754
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-07
- Primary completion
- 2023-07-30
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.